Fig. 2: cKOkif5b mice exhibit an impaired tumour response.
a Tumour growth curves for WT (blue line) or cKOKif5b (orange line) mice injected subcutaneously with B16-OVA cells and adoptively transferred with OT-I T cells (WT purple line, cKOKif5b yellow line). Tumour growth was monitored daily, and non-survival was defined as ulceration of the tumour or a mean tumour diameter of 15 mm. The data are quoted as the mean ± SEM from two independent experiments (WT, WT OT1, cKOKif5b n = 10 mice per group, cKOKif5b OT1 n = 9 mice). Statistical significance was determined by the two-way ANOVA and Sidak test’s correction for multiple comparison. *P < 0.05; **P < 0.005; ***P < 0.0001. b Survival curves for WT or cKOKif5b mice, treated as in a. Statistical significance was determined by the log-rank test and by the Gehan–Breslow–Wilcoxon test. *P < 0.05; **P < 0.005. c Mice were injected with Violet-labelled transgenic OT-I T cells and primed 1 day later with CD11c/P3UOVA (WT blue line or circles, cKOKif5b red line or circles; WT mice n = 7, cKOKif5b mice n = 7). The left panel shows representative profiles gated on CD8+, TCR Vα2+ cells. Statistical analysis of the division index is shown in the right panel: **P < 0.005 in a two-tailed unpaired Student’s t test. Graph shows mean ± S.E.M.
